Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020;25(8):705-708.
doi: 10.5863/1551-6776-25.8.705. Epub 2020 Nov 13.

Rapid Infliximab Infusion in the Pediatric Population

Erin J Munsel  1 , Peter J Bryan  1 , Bryce A Binstadt  2 , Danielle Bullock  2 , Colleen K Correll  2 , Elissa M Downs  3 , Patricia M Hobday  2 , Catherine Larson-Nath  3 , Boris Sudel  3 , Richard K Vehe  2
Affiliations

Rapid Infliximab Infusion in the Pediatric Population

Erin J Munsel et al. J Pediatr Pharmacol Ther. 2020.

Abstract

Objectives: To compare infusion reaction rates between rapid infliximab (REMICADE, Janssen Biotech Inc) infusions and previous standard 2- to 3-hour infusions; additionally, to assess patient satisfaction and reduction in chair time associated with rapid infliximab infusions.

Methods: Pediatric rheumatology and gastroenterology patients receiving maintenance infliximab therapy using a standard 2- to 3-hour titrated infusion had the opportunity to enroll in the non-titrated rapid 1-hour infusion protocol following tolerance of induction dosing at 0, 2, and 6 weeks. Patients were included from December 1, 2017, to March 31, 2018, via retrospective chart review and patient satisfaction surveys.

Results: Data were collected on 55 patients receiving a total of 160 rapid infliximab infusions. There were 2 infusion reactions during the enrollment and data collection period, resulting in an overall infusion reaction rate of 1.3%. The patient satisfaction survey results showed all patients were at minimum satisfied with the information provided regarding rapid infliximab, decreased time spent in clinic, ease of scheduling, and overall process.

Conclusions: Our data suggest rapid infliximab infusions are safe in pediatric rheumatology and gastroenterology patients receiving maintenance infliximab infusion therapy. The overall infusion reaction rate of 1.3% in this study is well below the accepted infusion reaction rate of standard-length infliximab infusions of 2% to 3%.

Keywords: gastroenterology; infliximab; infusion; pediatric; reaction; rheumatology.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria. The authors had full access to all of the data in the study and take full responsibility for the integrity of the data and accuracy of the data analysis.

References

    1. O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(1):1–6. - PubMed
    1. Neef HC, Riebschleger MP, Adler J. Meta-analysis: rapid infliximab infusions are safe. Aliment Pharmacol Ther. 2013;38(4):365–376. - PubMed
    1. Yeckes AR, Hoffenberg EJ. Rapid infliximab infusions in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009;49(1):151–154. - PubMed
    1. Bañuelos-Ramírez D, Ramírez-Palma MM, Balcázar-Sánchez ME et al. Rapid application of infliximab. Efficacy and complications [in Spanish] Reumatol Clin. 2007;3(4):171–175. - PubMed
    1. Befrits R, Malmström L, Forsell A et al. M1707 one hour infliximab infusion can replace two hour infusion in maintenance treatment of Crohns disease without shortcomings, in patients treated for up to three years. Gastroenterology. 2008;134(4):A402.

LinkOut - more resources